Evidence map›Paper›PMID 39641790›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2025

Evaluating the impact of cardiac substructure dosimetric parameters on survival in lung cancer patients undergoing postoperative radiotherapy.

Melek Tugce Yilmaz, Pervin Hurmuz, Ezgi Gurlek, Demet Yildiz, Mustafa Cengiz

Abstract read
PubMed Publisher
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Melek Tugce YilmazDepartment of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey. mlktgcylmz@gmail.com.ORCID 0000-0001-9813-9286
Pervin HurmuzDepartment of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.ORCID 0000-0003-1221-9192
Ezgi GurlekDepartment of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Demet YildizDepartment of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Mustafa CengizDepartment of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.ORCID 0000-0003-3692-8532

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe association of cardiac dosimetric parameters with survival in lung cancer patients is well established. However, most research has concentrated on patients undergoing definitive treatment. This study aims to investigate the relationship between cardiac dosimetric parameters and survival in patients receiving postoperative radiotherapy (PORT).

methodsSixty patients who received PORT between 2011 and 2021 were retrospectively evaluated. The substructures of the heart were delineated on the simulation computed tomography scans of the patients. Univariate and multivariate Cox regression analyses were conducted to investigate the correlation between dosimetric parameters and overall survival. The Statistical Package for the Social Sciences (SPSS) version 23.0 (IBM Corp., Armonk, NY, USA) was utilized for statistical analyses.

resultsRight atrium (RA) maximum dose (Dmax) was the only variable that was significantly associated with a shorter OS. Further receiver operating characteristic (ROC) analysis revealed that the optimum cut-off value for RA Dmax was 43.6 Gy, with a sensitivity of 69% and a specificity of 62%. In addition, inclusion of the upper right paratracheal (2R), lower right paratracheal (4R), left pulmonary ligament (9L), and right hilus (10R) lymphatic stations in the treatment field led to an increase in RA Dmax.

conclusionThe results of this retrospective study show that RA Dmax appears to have an impact on overall survival in patients undergoing PORT. Limiting the RA Dmax dose to below 43.6 Gy and avoiding elective nodal irradiation might potentially enhance survival in this patient cohort.

Indexed as

Heart AtriaLung NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRadiotherapy, AdjuvantRadiotherapy DosageRetrospective StudiesTomography, X-Ray ComputedCardiac toxicityElective nodal irradiationHeart dosePost-operative thoracic radiotherapyRight atrium

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.